9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis

Launched by BRIGHAM AND WOMEN'S HOSPITAL · Aug 10, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called Ofatumumab in patients with relapsing forms of multiple sclerosis (MS). Specifically, the trial aims to understand how Ofatumumab influences the activity of certain immune cells in the brain known as microglia over a period of 9 months. Researchers will also look at how changes in these cells relate to other markers in the blood and MRI scans, which can show how the disease is progressing.

To participate in this trial, individuals must be between 18 and 60 years old and have been diagnosed with active relapsing MS, meaning they have experienced at least one relapse in the past year or have MRI evidence of disease activity. Participants should be able to comply with the study procedures and agree to start treatment with Ofatumumab. Throughout the trial, participants will undergo various assessments, including blood tests and imaging scans, to monitor their health and the medication's effects. This study is currently recruiting participants, and it is important for potential volunteers to discuss any other health conditions or medications they are taking with their doctor to ensure they meet the eligibility criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with active, relapsing MS course. Active disease is defined by at least 1 relapse during the previous 1 year or 2 relapses during the previous 2 years or a positive gadolinium-enhancing MRI scan or MRI scan with new or unequivocally enlarging T2 lesions in previous year.
• • Age 18 to 60 years
• • EDSS 0 to 5.5
• • Subjects either untreated or treated with disease modifying therapies other than those listed in exclusion criteria
• • Agree to start treatment with ofatumumab and comply with study procedures for the duration of the study
• • No other systemic disease or neurological disorders requiring chronic or acute steroid or other immunosuppressive treatment
• • No known hypersensitivity reactions to contrast agents
• • None of the exclusion criteria
• Exclusion Criteria:
• • Subjects suspected of not being able or willing to cooperate or comply with study protocol requirements in the opinion of the investigator.
• • Subjects with primary progressive MS or SPMS without disease activity.
• • Disease duration of more than 10 years in patients with an EDSS score of 2 or less
• • Subjects meeting criteria for neuromyelitis optica.
• • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
• • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for at least 6 months after stopping study medication.
• • Subjects with active chronic disease (or stable but treated with immune therapy) of the immune system other than MS or with an immunodeficiency syndrome.
• * Subjects with a history of the following:
• • 1. History of malignancy
• • 2. History of alcohol or drug abuse
• • 3. Primary or secondary immunodeficiency
• • 4. Prior hematopoietic stem cell transplantation
• • 5. History of transplantation or anti-rejection therapy
• • Subjects with abnormal CD19, WBC, lymphocyte counts or abnormal IgG levels
• • Subjects with active systemic bacterial, viral or fungal infections, or known to have acquired immunodeficiency syndrome (AIDS).
• • Subjects with neurological symptoms consistent with PML or confirmed PML.
• • Subjects at risk of developing or having reactivation of syphilis or tuberculosis (eg subjects with known exposure to, or history of syphilis, or active or latent tuberculosis, even if previously treated). Testing for syphilis and tuberculosis will be done at Screening.
• • Subjects with low affinity binders (LAB) for TSPO radioligand
• • Subjects with abnormal serum creatinine levels
• • Subjects with any contraindications to PET/CT or MRI procedures (e.g. claustrophobia, MRI-incompatible implants or pacemakers, renal failure)
• * Subjects treated with other disease modifying treatments within their respective pre-specified washout periods will be excluded: